Abstract
Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint against immune over-activation through its interaction with Programmed death receptor 1 (PD-1) expressed on activated lymphocytes. PD-L1 expression was found to be enhanced by chemotherapy through different proliferation pathways. However, the predictive and prognostic value for PD-L1 expression in cancer patients treated with neoadjuvant chemotherapy (NAC) is not yet established. This review focused on the potential effects of chemotherapy on PD-L1 expression and the role of PD-L1 as a prognostic and predictive marker in NAC-treated cancer patients. In addition, the potential use of this marker in clinical practice is discussed.
Publication details
- DOI
- 10.18295/squmj.2019.19.04.002
- Journal
- Sultan Qaboos University Medical Journal, 19(4), e277-283
- Publisher
- Sultan Qaboos University
- Open access
- Gold open access
- License
- CC BY-ND 4.0
Cite this article
APA 7
Al-Dughaishi, M., Shalaby, A., Boudaka, K., Ammar, Boulassel, M. R., & Saleh, J. (2025). The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy. Sultan Qaboos University Medical Journal, 19(4), e277-283. https://doi.org/10.18295/squmj.2019.19.04.002
MLA 9
Al-Dughaishi, Malika, et al. "The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy." Sultan Qaboos University Medical Journal, vol. 19, no. 4, 2025, pp. e277-283. https://doi.org/10.18295/squmj.2019.19.04.002.
Chicago (author–date)
Al-Dughaishi, Malika, Asem Shalaby, Khawla Boudaka, Ammar, Mohamed Rachid Boulassel, and Jumana Saleh. 2025. "The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy." Sultan Qaboos University Medical Journal 19 (4): e277-283. https://doi.org/10.18295/squmj.2019.19.04.002.
Harvard
Al-Dughaishi, M., Shalaby, A., Boudaka, K., Ammar, Boulassel, M. R. and Saleh, J. (2025) 'The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy', Sultan Qaboos University Medical Journal, 19(4), pp. e277-283. doi:10.18295/squmj.2019.19.04.002.
Vancouver
Al-Dughaishi M, Shalaby A, Boudaka K, Ammar, Boulassel MR, Saleh J. The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy. Sultan Qaboos University Medical Journal. 2025;19(4):e277-283. doi:10.18295/squmj.2019.19.04.002
IEEE
M. Al-Dughaishi, A. Shalaby, K. Boudaka, Ammar, M. R. Boulassel, and J. Saleh, "The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy," Sultan Qaboos University Medical Journal, vol. 19, no. 4, pp. e277-283, 2025, doi: 10.18295/squmj.2019.19.04.002.